Learn More
≥98% HPLC PURITY
Retatrutide
5mg / 10 VIALS
MINDTEK · RESEARCH USE ONLY
RESEARCH USE ONLY COA VERIFIED SOLUTION PHASE

Retatrutide

GIP / GLP-1 / Glucagon Triple Agonist

39-amino-acid triagonist peptide with a C20 fatty-diacid side chain. Balanced agonism at the GIP, GLP-1, and glucagon receptors, driving glucoregulation and energy expenditure.

MW: 4731.33 Da CAS: 2381089-83-2 Per Vial: 5mg Kit: 10 Vials
SELECT QUANTITY
1 Vial $100Order
3 Vials Save 11%$89 eaOrder
5 Vials Save 15%$85 eaOrder
10 Vials Best Value$80 eaOrder

Mechanism of Action

Retatrutide co-activates three metabolic receptors: GIP, GLP-1, and glucagon (GCGR). The GLP-1 and GIP arms enhance glucose-dependent insulin secretion and satiety, while the glucagon arm raises energy expenditure and hepatic lipid oxidation in research models, a mechanism absent from single- and dual-agonists.

⚡
GLP-1 Receptor Agonism
Glucose-dependent insulinotropic signalling and central appetite suppression.
🔬
GIP Receptor Agonism
Incretin-axis potentiation of insulin response and lipid handling.
🧬
Glucagon (GCGR) Agonism
Increased energy expenditure and hepatic lipid oxidation documented in research models.

Research Evidence

DATA = directly reported in cited study · INFERENCE = derived · SPECULATION = hypothesis

Coskun T et al. (2022) Cell Metab 34(9)DATA
Retatrutide (LY3437943), a GIP/GLP-1/glucagon triagonist, produced greater weight and glucose effects than dual agonism in preclinical models (DATA).
Jastreboff AM et al. (2023) N Engl J Med 389(6)DATA
Phase 2 obesity trial: up to 24.2% mean body-weight reduction at 48 weeks vs. placebo (DATA).
Rosenstock J et al. (2023) Lancet 402(10401)DATA
Phase 2 type-2-diabetes trial: dose-dependent HbA1c and body-weight reductions over 36 weeks (DATA).

Certificate of Analysis

Every Mindtek batch is independently tested before release. We were among the first peptide suppliers in Southeast Asia to implement mandatory third-party HPLC verification — a standard, not an exception.

HPLC Purity≥98.0%
Bacterial Endotoxins≤5 EU/mg
Water Content (Karl Fischer)≤8.0%
Peptide Content≥80%
StandardUSP/EP

Research Protocol Reference

For laboratory research use only — not for human or veterinary use.

💧
Reconstitution
Add sterile bacteriostatic water (0.9% benzyl alcohol) slowly against the vial wall. Gently swirl — do not vortex. Allow 5 min for complete dissolution.
🧊
Storage
Store solution-phase at -20°C. Post-reconstitution: maintain at 2–8°C, use within 28 days. Protect from light. Avoid repeated freeze-thaw cycles.
📐
Administration
SubQ or IM administration in standard research protocols. Insulin syringe recommended for precise dosing. Refer to published literature for compound-specific protocols.

Frequently Asked Questions

What is Retatrutide?
Retatrutide is a 39-amino-acid synthetic peptide (triple GIP/GLP-1/glucagon receptor agonist) engineered from a GIP peptide backbone. Research applications: metabolic, energy-expenditure, and glucoregulatory studies. Research use only.
How is Mindtek Retatrutide produced?
Synthesised via solid-phase peptide synthesis (SPPS). Each batch: HPLC purity verification (≥99.3%), mass spectrometry identity, endotoxin testing prior to release.
Storage requirements?
Store solution-phase Retatrutide at -20°C. Post-reconstitution with sterile BAC water: 2–8°C, use within 28 days. Avoid repeated freeze-thaw cycles.

Ready to Order Retatrutide?

Mindtek ships solution-phase, independently verified research compounds to qualified researchers globally. First in Southeast Asia.

Place an Order Research Hub